Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Newpath Partners
BioCentury | Jan 11, 2025
Finance
Metsera, Maze will play canary in the IPO coal mine
Pair of Arch, Ra portfolio companies file to list on NASDAQ
BioCentury | Dec 12, 2024
Deals
Nvelop, Chroma merger creates opportunity for targeted epigenome editors
Nvelop CEO Jeff Walsh will lead nChroma, which has $75M in new funding and a lead for HBV
BioCentury | Aug 30, 2024
Emerging Company Profile
Nvelop: Delivering gene editors to specific cells via virus-like particles
Propelled by $100M in seed funding, Cambridge, Mass.-based biotech is developing dual virus-like particle platforms from two gene editing pioneers
BioCentury | Jul 25, 2024
Finance
Venture Report: Third Arc’s $165M series A; Brenig heads for clinic with $65M round
Plus: Flagship-backed Abiologics launches; and rounds for GRO, Autobahn and Rona
BioCentury | Apr 18, 2024
Finance
Venture report: Metsera’s $290M launch, Regeneron’s new VC fund
Plus fundings for Asher, Pathios, Outrun and Theolytics
BioCentury | Apr 12, 2024
Finance
Venture report: Torl doubles its series B funding in Deep Track-led B2
Plus: PureTech’s Seaport launches, and updates from Nvelop, D3 Bio and more
BioCentury | Jan 13, 2024
Finance
Jan. 12 Quick Takes: Alto Neuroscience files for IPO
Plus: Company-creating research institute Arena BioWorks launches in Kendall Square, and an update from Ji Xing
BioCentury | Sep 19, 2023
Emerging Company Profile
Magnet: taking molecular glues beyond protein degradation with $50M
The company discovers small molecules that induce desired protein-protein interactions using an arsenal of screening technologies
BioCentury | May 18, 2023
Regulation
May 18 Quick Takes: Vaccines panel backs Pfizer RSV vaccine
Plus: Pressure mounts on CMS over Alzheimer’s therapies, financing updates for Coherent, Myeloid, Cabaletta, RedCloud, CytoCares, and more
BioCentury | Apr 26, 2023
Finance
April 26 Quick Takes: Orbital’s $270M A round is year’s largest so far
Plus: Medicare to cover Leqembi, if approved; Sangamo restructuring; and updates from Roche, GSK, Seres and more
Items per page:
1 - 10 of 23